Clinical Trial

IIT2025-03-YANG-LIFT-HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patients may become eligible for a liver transplant. The investigators will also closely watch for side effects from the study treatments. Section 2 has more details.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-19.
Trial Details
NCT Number NCT07489976
Lead Sponsor Ju Dong Yang
Conditions Hepato Cellular Carcinoma
Enrollment 41 participants
Start Date 2026-04-01
Primary Completion 2030-04-01 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-27